Description: Cancer immunotherapies have rapidly expanded with the development of innovative treatments such as immune checkpoint inhibitors, adoptive cell therapy, and cancer vaccines. T cell therapies with genetic modifications have shown effective tumor suppression through activation of T cells by tumor antigens. While CAR-T cell therapy demonstrated remarkable clinical efficacies in hematological malignances, similar therapeutic benefits have not been achieved in solid tumors. TCR-T cell therapy offered a promising alternative treatment option, which showed significant efficacies in multiple types of solid cancers. However, hurdles need to be overcome to further improve the safety and potency with deeper understanding of the regulation and crosstalk among TCR-T therapy, tumor, and host environment. Gut microbiome has been increasingly recognized as an essential modulator of cancer therapies, including immunotherapies. Recent studies found that antibiotics treatment could lower the objective response rate to immune checkpoint inhibitors. Likewise, broad-spectrum antibiotics treatment prior to CD19-targeted CAR-T cell therapy was associated with increased adverse outcomes. However, the functional relationship between the status of gut microbiome and the response to TCR-T therapy has not been described yet. The study conducted metagenomics sequencing on fecal samples of mice with human melanoma xenograft and elaborated the alteration of gut microbiota during CD8+ TCR-T infusion.

Data type: Metagenome

Sample scope: Multiisolate

Relevance: Medical

Release date: 2024-07-03

Last updated: 2024-07-03

Data size: 2.25TB